WCLC 2025 - Posters & ePosters-EP.11.09 Predictive Value of Markers of Systemic Inflammation in Patients With Advanced NSCLC Treated With First-Line Immune Checkpoint Inhibitors

EP.11.09 Predictive Value of Markers of Systemic Inflammation in Patients With Advanced NSCLC Treated With First-Line Immune Checkpoint Inhibitors

Back to course

Pdf Summary

This retrospective study from the Institute for Oncology and Radiology of Serbia assessed the predictive value of systemic inflammation markers in 100 patients with advanced non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab, an immune checkpoint inhibitor (ICI). The markers analyzed included neutrophil-to-lymphocyte ratio (NLR), Lung Immune Prognostic Index (LIPI), and Glasgow Prognostic Score (GPS), all derived from routine blood tests. NLR was calculated from neutrophil and lymphocyte counts; LIPI combined derived NLR (dNLR) and lactate dehydrogenase (LDH) levels into good, intermediate, and poor prognostic groups; GPS used C-reactive protein and albumin levels to stratify patients.<br /><br />Results showed that patients with lower systemic inflammation markers (NLR ≤4.46, good LIPI, and GPS 0) tended to have longer progression-free survival (PFS) and overall survival (OS), although these differences did not reach statistical significance—likely due to small subgroup sizes. Median PFS for good LIPI was not reached versus 16.43 months for intermediate and 12.45 months for poor LIPI. Correspondingly, median OS was not reached in good LIPI, 18.17 months for intermediate, and 11.04 months for poor groups. Similarly, patients with GPS 0 showed higher median PFS (23.53 months) and OS (31.73 months) compared to GPS 1 and 2, but without significant p-values. NLR also showed a trend toward better survival with lower values.<br /><br />The study concludes that lower systemic inflammation correlates with improved survival in advanced NSCLC patients receiving ICIs, but statistical significance was not achieved. Larger patient cohorts are being investigated to validate these inexpensive, easily measured inflammatory biomarkers as predictive tools for ICI treatment response.

Asset Subtitle

Katarina Ljujic

Meta Tag

Speaker Katarina Ljujic

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

non-small cell lung cancer

NSCLC

systemic inflammation markers

neutrophil-to-lymphocyte ratio

NLR

Lung Immune Prognostic Index

LIPI

Glasgow Prognostic Score

GPS

pembrolizumab